What is the recommended management for type 2 diabetes mellitus?

Management of Type 2 Diabetes Mellitus

Start metformin immediately at diagnosis alongside lifestyle modifications (diet and exercise), then add SGLT2 inhibitors or GLP-1 receptor agonists based on the presence of cardiovascular disease, chronic kidney disease, heart failure, or obesity—not simply when A1C targets are unmet. 1, 2

Initial Therapy

Metformin as Foundation

• Initiate metformin at or soon after diagnosis unless contraindicated or not tolerated 3
• Start at low dose with gradual titration to minimize gastrointestinal side effects 3
• Metformin remains the most cost-effective first-line agent with proven efficacy 3

When to Skip Metformin Monotherapy

• If A1C ≥9.0% at diagnosis: Start combination therapy immediately with two non-insulin agents or consider insulin 3
• If A1C ≥10% or glucose ≥300 mg/dL with symptoms: Initiate insulin therapy regardless of other medications 1
• If catabolic features present (unexpected weight loss, ketonuria): Insulin is mandatory 3

Comorbidity-Driven Second-Line Therapy

Heart Failure (Any Ejection Fraction)

• Add SGLT2 inhibitor for glycemic management and prevention of heart failure hospitalizations, regardless of current A1C 1, 2
• This recommendation applies even if glucose control is adequate 2

Chronic Kidney Disease

• If eGFR 20-60 mL/min/1.73 m² and/or albuminuria: Add SGLT2 inhibitor to minimize CKD progression, reduce cardiovascular events, and prevent heart failure hospitalizations 1
• Note: Glycemic benefits of SGLT2 inhibitors diminish at eGFR <45 mL/min/1.73 m² 1
• If eGFR <30 mL/min/1.73 m²: Prefer GLP-1 RA for glycemic management due to lower hypoglycemia risk and cardiovascular event reduction 1

Established Atherosclerotic Cardiovascular Disease

• Prefer GLP-1 RA (including dual GIP/GLP-1 RA) for superior reduction in major adverse cardiovascular events 1
• SGLT2 inhibitors are also beneficial but GLP-1 RAs show stronger MACE reduction 4

Obesity (BMI ≥30 kg/m²)

• Add GLP-1 RA or dual GIP/GLP-1 RA for both glycemic control and weight loss (typically >5%, often >10%) 1, 2, 5
• High-potency GLP-1 RAs and dual GIP/GLP-1 RAs produce the greatest weight reduction 5

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

• If overweight/obese with MASLD: Consider GLP-1 RA or dual GIP/GLP-1 RA 2
• If biopsy-proven MASH or high risk for liver fibrosis: Prefer pioglitazone, GLP-1 RA, or dual GIP/GLP-1 RA 2

Escalation Strategy

Early Combination Therapy

• Consider starting two agents simultaneously at diagnosis to shorten time to glycemic goals, especially if A1C >8.5% or in younger patients with type 2 diabetes 1, 6
• This proactive approach prevents therapeutic inertia 6

Reassessment Timeline

• Evaluate treatment response every 3-6 months 3, 1
• If A1C target not achieved within 3 months, intensify therapy immediately—do not delay 3, 7

Third-Line Options

• Combine agents with complementary mechanisms of action 6
• Emerging evidence supports combining SGLT2 inhibitors with GLP-1 RAs for additive effects on weight, glucose, and potentially cardiorenal outcomes 6
• Consider DPP-4 inhibitors, thiazolidinediones, or sulfonylureas based on individual factors 3

Insulin Therapy

When to Initiate Insulin

• Mandatory indications: A1C >10%, glucose ≥300 mg/dL with symptoms, catabolic features, or ketonuria 1
• Many patients ultimately require insulin due to progressive β-cell dysfunction 3

Insulin Initiation Strategy

• Start with basal insulin (glargine or detemir preferred over NPH for less nocturnal hypoglycemia) added to existing therapy 3
• Discontinue sulfonylureas when starting insulin to reduce hypoglycemia risk 6
• GLP-1 RA is preferred over insulin when both are options 1

Combination with GLP-1 RA

• If insulin is used, combine with GLP-1 RA or dual GIP/GLP-1 RA for greater glycemic effectiveness, beneficial weight effects, and reduced hypoglycemia risk 1
• Reassess and reduce insulin doses when adding or escalating GLP-1 RA 1

Prandial Insulin

• Add rapid-acting insulin analogs (lispro, aspart, glulisine) if basal insulin alone is insufficient due to progressive β-cell failure 3
• These provide better postprandial control than regular insulin 3

Critical Pitfalls to Avoid

Therapeutic Inertia

• The average time to add a second agent is 5-19 months—this is unacceptably long 7
• Do not wait beyond 3 months if targets are unmet 3, 7

Ignoring Comorbidities

• Cardiovascular and renal protection must drive drug selection, not just A1C reduction 3, 6
• The shift from glucose-centric to complications-centric management is evidence-based 6, 8

Delaying Insulin When Indicated

• Severe hyperglycemia with symptoms requires immediate insulin—do not attempt oral agents first 3
• Once symptoms resolve, insulin can often be tapered and replaced with non-insulin agents 3

Medication Continuation Errors

• Continue metformin and other agents when adding insulin unless contraindicated 1
• Exception: Stop sulfonylureas to prevent hypoglycemia 6

Patient Education Requirements

• Glucose monitoring techniques and interpretation 3
• Insulin injection technique and storage 3
• Recognition and treatment of hypoglycemia 3
• Sick day management rules 3
• Certified diabetes educators are invaluable when available 3

De-intensification Considerations

• Reduce or stop hypoglycemia-causing medications if A1C is substantially below target (<6.5%) or when adding new glucose-lowering agents 6
• Consider de-intensification in frail older adults or those with changed clinical circumstances 6